Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.

Pathophysiology of Diabetic Dyslipidemia

Open access
Hirano, Tsutomu · 2018 · Journal of Atherosclerosis and Thrombosis

Abstract

Accumulating clinical evidence has suggested serum triglyceride (TG) is a leading predictor of atherosclerotic cardiovascular disease, comparable to low-density lipoprotein (LDL)-cholesterol (C) in populations with type 2 diabetes, which exceeds the predictive power of hemoglobinA1c. Atherogenic dyslipidemia in diabetes consists of elevated serum concentrations of TG-rich lipoproteins (TRLs), a high prevalence of small dense low-density lipoprotein (LDL), and low concentrations of cholesterol-rich high-density lipoprotein (HDL)2-C. A central lipoprotein abnormality is an increase in large TG-rich very-low-density lipoprotein (VLDL)1, and other lipoprotein abnormalities are metabolically linked to increased TRLs. Insulin critically regulates serum VLDL concentrations by suppressing hepatic VLDL production and stimulating VLDL removal by activation of lipoprotein lipase. It is still debated whether hyperinsulinemia compensatory for insulin resistance is causally associated with the overproduction of VLDL. This review introduces experimental and clinical observations revealing that insulin resistance, but not hyperinsulinemia stimulates hepatic VLDL production. LDL and HDL consist of heterogeneous particles with different size and density. Cholesterol-depleted small dense LDL and cholesterol-rich HDL2 subspecies are particularly affected by insulin resistance and can be named "Metabolic LDL and HDL," respectively. We established the direct assays for quantifying small dense LDL-C and small dense HDL(HDL3)-C, respectively. Subtracting HDL3-C from HDL-C gives HDL2-C. I will explain clinical relevance of measurements of LDL and HDL subspecies determined by our assays. Diabetic kidney disease (DKD) substantially worsens plasma lipid profile thereby potentiated atherogenic risk. Finally, I briefly overview pathophysiology of dyslipidemia associated with DKD, which has not been so much taken up by other review articles.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5551/jat.rv17023

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Pathogenesis of insulin resistance on VLDL overproduction and its related changes in other lipoproteins. Hepatic VLDL1 production is stimulated by insulin resistance, which is a central lipoprotein abnormality in diabetic dyslipidemia. The major sources of triglyceride (TG) in the liver are 1) free fatty acid (FFA) derived from adipose, 2) fatty acids derived from remnants of TRL (VLDL and chylomicron), and 3) de Novo Lipogenesis (DNL). Newly synthesized TG suppress intracellular apoB degradation. Insulin resistance is associated with reduced inhibition of hormone-sensitive lipase in adipose tissue, thereby augmented portal flux of FFA. TG synthesis from FFA or FFA per se strongly inhibit apoB degradation in the liver, thereby stimulates VLDL production. Hepatic uptake of TG-rich lipoprotein (TRL) remnants and DNL supply TG in the liver, but the contribution of these two factors to suppress apoB degradation are minor. Insulin resistance suppresses phosphoinositide (PI) 3-kinase mediated apoB degradation and enhances the action of microsomal triglyceride transfer protein (MTP), a rate-limiting factor of VLDL assembly. In the insulin-resistant state, VLDL1 production is preferentially increased without affecting VLDL2 production. Overproduction of VLDL1 is metabolically associated with preponderance of small dense LDL and reduced large cholesterol-rich HDL2.
Fig. 1. Pathogenesis of insulin resistance on VLDL overproduction and its related changes in other lipoproteins. Hepatic VLDL1 production is stimulated by insulin resistance, which is a central lipoprotein abnormality in diabetic dyslipidemia. The major sources of triglyceride (TG) in the liver are 1) free fatty acid (FFA) derived from adipose, 2) fatty acids derived from remnants of TRL (VLDL and chylomicron), and 3) de Novo Lipogenesis (DNL). Newly synthesized TG suppress intracellular apoB degradation. Insulin resistance is associated with reduced inhibition of hormone-sensitive lipase in adipose tissue, thereby augmented portal flux of FFA. TG synthesis from FFA or FFA per se strongly inhibit apoB degradation in the liver, thereby stimulates VLDL production. Hepatic uptake of TG-rich lipoprotein (TRL) remnants and DNL supply TG in the liver, but the contribution of these two factors to suppress apoB degradation are minor. Insulin resistance suppresses phosphoinositide (PI) 3-kinase mediated apoB degradation and enhances the action of microsomal triglyceride transfer protein (MTP), a rate-limiting factor of VLDL assembly. In the insulin-resistant state, VLDL1 production is preferentially increased without affecting VLDL2 production. Overproduction of VLDL1 is metabolically associated with preponderance of small dense LDL and reduced large cholesterol-rich HDL2.CC BY-NC-SA · PubMed Central
Fig. 2. Overproduction of TG-rich lipoproteins creates small dense LDL. Production of VLDL and chylomicrons (TG-rich lipoproteins (TRLs)) is stimulated in individuals with type 2 diabetes. The long residence time of TRLs in circulation promotes excessive transfer of TG to LDL and a concomitant transfer of cholesteryl esters (CE) to TRLs via the action of cholesteryl ester transfer protein (CETP). Hepatic TG lipase-mediated hydrolysis of core TG produces cholesterol-poor LDL particles (small dense LDL).
Fig. 2. Overproduction of TG-rich lipoproteins creates small dense LDL. Production of VLDL and chylomicrons (TG-rich lipoproteins (TRLs)) is stimulated in individuals with type 2 diabetes. The long residence time of TRLs in circulation promotes excessive transfer of TG to LDL and a concomitant transfer of cholesteryl esters (CE) to TRLs via the action of cholesteryl ester transfer protein (CETP). Hepatic TG lipase-mediated hydrolysis of core TG produces cholesterol-poor LDL particles (small dense LDL).CC BY-NC-SA · PubMed Central
Fig. 3. Relationship between LDL-C and small dense LDL-C concentrations in healthy controls, patients with type 2 diabetes without coronary heart diseases (CAD), and patients with CAD including diabetes. SdLDL-C levels corresponding to LDL-C levels are higher in patients with diabetes or CAD than in healthy controls. This figure is made based on our original data published in reference (80).
Fig. 3. Relationship between LDL-C and small dense LDL-C concentrations in healthy controls, patients with type 2 diabetes without coronary heart diseases (CAD), and patients with CAD including diabetes. SdLDL-C levels corresponding to LDL-C levels are higher in patients with diabetes or CAD than in healthy controls. This figure is made based on our original data published in reference (80).CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 102 references

Cited by

See all 552

Metadata

Authors
Hirano, T.
Affiliations
SHOWA Medical University (JP)
Corresponding author
Hirano, Tsutomu
Venue
Journal of Atherosclerosis and Thrombosis
Published
2018-09-01
Volume
25
Issue
9
Pages
771-782
ISSN
  • 1340-3478 (ISSN-L)
  • 1880-3873
OpenAlex
W2820707192
Cited by
552
References
102
Citations by year
2026: 65 · 2025: 90 · 2024: 81 · 2023: 86 · 2022: 88 · 2021: 70 · 2020: 46 · 2019: 21 · 2018: 4
FWCI
5.42
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • Journal of Atherosclerosis and Thrombosis (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords
diabetic dyslipidemia, type 2 diabetes, triglyceride-rich lipoproteins, VLDL, small dense LDL, HDL2, HDL3 cholesterol, insulin resistance, hyperinsulinemia, lipoprotein lipase, atherosclerotic cardiovascular disease, diabetic nephropathy, plasma lipid profile
MeSH terms
Pioglitazone, Animals, Cholesterol, Chylomicrons, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Fatty Acids, Nonesterified, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Lipoproteins, Cholesterol, HDL, Cholesterol, LDL, Lipoproteins, VLDL, Liver, Risk, Triglycerides, Cholesterol, VLDL, Dyslipidemias, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pathophysiology of Diabetic Dyslipidemia. https://app.cochat.ai/papers/10.5551/jat.rv17023
The paper
Hirano, T. (2018). Pathophysiology of Diabetic Dyslipidemia. Journal of Atherosclerosis and Thrombosis. https://doi.org/10.5551/jat.rv17023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.